STRATA Skin Sciences(NASDAQ:SSKN) reported its second-quarter 2025 results on August 13, 2025, highlighting significant developments in reimbursement expansion, ongoing litigation, and commercial ...

GAAP revenue was $2.7 million for Q2 2025, missing analyst estimates by 20.6%. Operating expenses surged, driven by costs tied to the ACELYRIN merger and clinical trial acceleration. The merger ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a study titled ‘Prospective ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, ...

Large cohort study finds TNF inhibitors linked to lower cancer risk in psoriasis, supporting long-term safety of biologic ...

APREMILAST demonstrated sustained efficacy and a consistent safety profile over 52 weeks in paediatric patients with moderate ...

A multicenter study finds no difference in outcomes between frail and nonfrail elderly patients treated with tildrakizumab ...

The biopharma’s campaign for the treatment, which received FDA approval late last year to treat HS, aims to help patients get back to daily activities.

Patients with severe psoriasis who were treated with TNFi long-term had a lower risk of developing PsA than those treated with phototherapy.

The analysis included data from 24 randomized clinical trials encompassing 12,661 patients. The findings revealed that interclass biologic switching in psoriasis treatment led to significantly ...